STOCK TITAN

Seven Fleet (NASDAQ: MANE) files 13D on Veradermics 0.2% equity stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Seven Fleet Master Fund LP and related entities filed a Schedule 13D on Veradermics, Inc., reporting beneficial ownership of 80,000 common shares, or 0.2% of 41,184,080 shares outstanding. The stake, held through Seven Fleet Master Fund, was acquired mainly in open-market and follow-on offering purchases.

The fund paid an aggregate purchase price of about $8,000,000 for these shares, including 80,000 shares bought at $100.00 per share in the issuer’s follow-on offering on May 1, 2026. The investors state they viewed the stock as undervalued and an attractive opportunity when purchased.

The filing outlines a flexible strategy: the group may buy more shares, sell shares, or engage in hedging, and may communicate with management, the board, other shareholders, or potential acquirers about capital allocation, ownership structure, a possible sale of the company or its parts, and board or operational changes.

Positive

  • None.

Negative

  • None.

Insights

Small 0.2% stake, but language leaves room for activist-style engagement.

The filing shows Seven Fleet Master Fund and affiliates owning 80,000 Veradermics shares, or 0.2% of 41,184,080 shares outstanding. The position cost about $8,000,000, including purchases at $100.00 per share in a follow-on offering on May 1, 2026.

The investors say they viewed the stock as undervalued and may increase or decrease their holdings. They explicitly reserve the right to discuss capital allocation, capitalization, ownership structure, a potential sale of the issuer, and board composition or operations.

The stake is relatively small, so influence depends on coordination with other holders and future actions. The filing notes policies with Longitude Capital, which may be deemed to beneficially own 4,653,873 shares (11.3%), while expressly disclaiming group status and beneficial ownership beyond directly held shares.

Shares owned 80,000 shares Beneficially owned Veradermics common stock
Ownership percentage 0.2% Portion of 41,184,080 Veradermics shares outstanding
Aggregate purchase price $8,000,000 Cost of 80,000 Veradermics shares, excluding commissions
Follow-on purchase price $100.00 per share Price paid on May 1, 2026 follow-on offering
Shares outstanding 41,184,080 shares Outstanding Veradermics shares used for percentage calculations
Longitude shares 4,653,873 shares Veradermics shares Longitude may be deemed to beneficially own
Longitude ownership 11.3% Longitude’s potential percentage of Veradermics outstanding shares
Schedule 13D regulatory
"This joint statement on is being filed by Seven Fleet Master Fund LP"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
beneficial owner financial
"shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d)"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
follow-on offering financial
"purchased 80,000 Shares at a purchase price of $100.00 per Share, excluding commissions, pursuant to the Issuer's follow-on offering"
A follow-on offering is when a company sells additional shares to the public after its initial stock listing to raise more cash. For investors it matters because the new shares increase the total number of shares outstanding, which can reduce each existing shareholder’s ownership share and earnings per share—similar to baking more loaves of bread after the first batch, which means each slice represents a slightly smaller piece of the whole; the funds raised can also support growth or pay debt.
margin loans financial
"purchased with working capital (which may, at any given time, include margin loans made by brokerage firms"
Margin loans are loans from a brokerage that let an investor borrow money using their existing stocks, bonds or cash as collateral to buy more securities. They matter because borrowing magnifies both gains and losses—like using a lever to move a heavier load—so small market moves can have outsized effects on your returns; investors also pay interest and risk a margin call, where the broker may force sales if collateral falls below required levels.
joint filing agreement regulatory
"entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing"
shared voting power financial
"Shared Voting Power 80,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.





922967104

(CUSIP Number)
Kelly Zelezen
Kleinberg, Kaplan, Wolff & Cohen, P.C., 500 Fifth Avenue
New York, NY, 10110
2129866000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
05/01/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Seven Fleet Master Fund LP
Signature:/s/ Dr. Brian Liu
Name/Title:Dr. Brian Liu, Managing Member of Seven Fleet Capital Management LP, its Investment Mgr and Seven Fleet Capital Management GP, LLC, its Gen'l Ptr
Date:05/05/2026
Seven Fleet Capital Management LP
Signature:/s/ Dr. Brian Liu
Name/Title:Dr. Brian Liu, Managing Member of Seven Fleet Capital Management GP, LLC, its General Partner
Date:05/05/2026
Seven Fleet Capital Management GP LLC
Signature:/s/ Dr. Brian Liu
Name/Title:Dr. Brian Liu, Managing Member
Date:05/05/2026
Brian Liu
Signature:/s/ Dr. Brian Liu
Name/Title:Dr. Brian Liu
Date:05/05/2026

FAQ

How many Veradermics (MANE) shares does Seven Fleet report owning in this Schedule 13D?

Seven Fleet Master Fund and related entities report beneficial ownership of 80,000 Veradermics common shares. This holding represents 0.2% of 41,184,080 shares outstanding, based on the issuer’s reported share count, and is held with shared voting and dispositive power among the reporting persons.

What percentage of Veradermics (MANE) does Seven Fleet’s 80,000-share position represent?

The filing states that Seven Fleet’s 80,000 Veradermics shares represent 0.2% of the class. This is calculated against 41,184,080 shares outstanding, combining shares from Veradermics’ Form 10-K and additional shares sold under its Form S-1 registration statements.

How much did Seven Fleet pay for its Veradermics (MANE) stake and at what price per share?

Seven Fleet Master Fund reports an aggregate purchase price of approximately $8,000,000 for the 80,000 Veradermics shares. The filing notes that on May 1, 2026, the fund bought 80,000 shares at $100.00 per share in Veradermics’ follow-on offering, excluding commissions.

Why did Seven Fleet invest in Veradermics (MANE) according to the Schedule 13D?

The reporting persons state they bought Veradermics shares because they believed the stock was undervalued and represented an attractive investment opportunity when purchased. They indicate they will continually review the investment as market conditions, Veradermics’ financial position, and share price evolve over time.

What future actions does Seven Fleet say it may take regarding its Veradermics (MANE) investment?

Seven Fleet may buy additional shares, sell shares, or hedge its position. It may also communicate with management, the board, other shareholders, or potential acquirers regarding capital allocation, capitalization, ownership structure, a possible sale of the issuer, board composition, or operational changes at Veradermics.

How many Veradermics (MANE) shares are outstanding and how is that number derived?

The Schedule 13D uses 41,184,080 shares outstanding. This combines 37,340,290 shares as of March 25, 2026 from Veradermics’ Form 10-K with 3,843,790 additional shares sold under its Form S-1 registration statements, as disclosed in the company’s Form 8-K.

What does the Schedule 13D say about Longitude Capital’s holdings in Veradermics (MANE)?

Based on information from Longitude, the filing states Longitude may be deemed to beneficially own 4,653,873 Veradermics shares, or 11.3% of outstanding shares. However, the Seven Fleet reporting persons expressly disclaim group membership and beneficial ownership of any shares beyond those they directly own.